A Pilot Study to Assess Body Mass Composition Using Bioimpedance Analysis and Muscle Ultrasound in Patients with Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis on Anti-fibrotic Medications

What this Trial Is About

Researchers are studying how anti-fibrotic medications affect body mass composition in patients with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). These medications, such as nintedanib and pirfenidone, often cause side effects like nausea and loss of appetite, which may change body fat and muscle amounts. Traditional methods like weight and BMI don't detect these changes well, so this study uses bioimpedance analysis (BIA) and muscle ultrasound to better measure body composition. The study involves patients newly starting anti-fibrotic drugs and a control group of patients with similar lung disease but not beginning these medications. BIA measures body composition quickly by attaching electrodes for about 6 seconds, while muscle ultrasound assesses thigh muscle size. Additional measurements include mid-arm circumference, physical tests like sit-to-stand and walking speed, and questionnaires on quality of life, physical activity, and gastrointestinal symptoms. Participants will provide a 3-day diet diary as well. Assessments occur before starting the medications and again after four months to track changes. Researchers will evaluate the feasibility of these measurements, the acceptability of BIA and ultrasound, and collect data on muscle strength, body weight, height, and questionnaires at both time points. The study aims to understand the impact of anti-fibrotic drugs on body composition and related physical functions in these patients over this period.

A Pilot Study to Assess Body Mass Composition Measurement Using BIA and Muscle Ultrasound in IPF and PPF Patients on Anti-fibrotic Medications